Clinical Trials Browser

Phase 2 × Active not recruiting × Medicare Part B × Clear all

NCT04624958 2024-10-18

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell